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Open access under CRetinoid treatment is suggested to promote development of inﬂammatory bowel disease, although pre-
clinical studies are not supportive. We evaluated the effect of retinoids on cytokine response in in vitro-
differentiated human dendritic cells (ivDCs) and macrophages (ivMACs) derived from healthy human
donors and in cultured human THP-1 cells. Effect on human intestinal epithelial cell integrity was also
assessed. Each cell type was incubated (±lipopolysaccharide [LPS]) with all-trans retinoic acid (ATRA),
13-cis-RA (isotretinoin) and 4-oxo-13-cis-RA. Cytokine analysis was performed by array analysis. Cul-
tured human endothelial colorectal adenocarcinoma (Caco-2) cells were incubated with these retinoids
and media analyzed for leakage by spectroﬂuorometric analysis. ATRA consistently and signiﬁcantly
inhibited LPS-induced release of the pro-inﬂammatory cytokines tumor necrosis factor, interleukin
(IL)-6, macrophage inﬂammatory protein (MIP)-1a and MIP-1b. All retinoids tested stimulated release
of the anti-inﬂammatory cytokines granulocyte–macrophage colony-stimulating factor and IL-10, and
also monocyte chemotactic protein-1, vascular endothelial growth factor and eotaxin-1. Incubation with
retinoids did not signiﬁcantly alter the permeability of Caco-2 monolayers. Pre-treatment of each cell
type with retinoids promoted an anti-inﬂammatory cytokine proﬁle with only minimal effect on intesti-
nal epithelial cell permeability; consistent with in vivo studies.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
There is currently much debate as to whether vitamin A and
associated retinoid derivatives are beneﬁcial or harmful to the gas-
trointestinal (GI) tract, a situation primarily driven by clinical case
reports claiming a putative causal relationship between retinoid
treatment with 13-cis-retinoic acid (13-cis-RA, isotretinoin) and
the occurrence of ulcerative colitis (UC) and Crohn’s disease (CD),oxo-13-cis-RA, 4-oxo-13-cis-
uman endothelial colorectal
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C BY-NC-ND license. i.e. two forms of chronic inﬂammatory bowel disease (IBD) (Crock-
ett et al., 2010; Reddy et al., 2006). Contrary to this, key basic re-
search data do, in fact, support anti-inﬂammatory effects of
retinoids on the GI tract (Bai et al., 2009; Iwata and Yokota,
2011). Nevertheless, the case for retinoids being beneﬁcial or
harmful to the GI tract has only infrequently been based on robust
scientiﬁc evidence and, thus far, it has not been possible to conﬁrm
or refute a causative relationship (Crockett et al., 2009). Ideally,
further prospective or well-designed retrospective pharmacoepi-
demiological studies are needed to deﬁnitively establish causality.
Understanding of the pathophysiology of IBD has markedly in-
creased recently with a number of pre-disposing genetic risk fac-
tors identiﬁed for CD and (to a lesser extent) UC, along with a
number of environmental triggers considered as potential key
mediators of disease development (Rogler, 2011). Although more
risk factors are expected to follow (Barrett et al., 2008; Latella
et al., 2010; Nguyen et al., 2006), the role of many these in the
pathophysiology of CD, for example, is unclear (Mathew, 2008)
and, nevertheless, account for only a fraction of observed CD inci-
dence (Torkamani et al., 2008). Key environmental triggers include
dietary factors, food additives or drugs (Cosnes, 2010; Hou et al.,
2011a,b; Järnerot et al., 1983; Katschinski et al., 1988; Martini
and Brandes, 1976; Silkoff et al., 1980; Thornton et al., 1979),
and cigarette smoking (Avidan et al., 2005; Cosnes et al., 2001,
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disease course (Cámara et al., 2010; Danese et al., 2004; Levenstein,
2002). Signiﬁcantly, the innate immune system and epithelial bar-
rier function are critical to the pathophysiology of both UC and CD;
thus, environmental triggers that inﬂuence the intestinal microbi-
ota and modify intestinal barrier function would appear particu-
larly relevant.
Recent studies in experimental models of IBD and in human
colonic biopsy samples have shown retinoids to be potentially
anti-inﬂammatory; for example, all-trans-retinoic acid (ATRA, tret-
inoin) and transforming growth factor (TGF)-b1 promoted differen-
tiation of FOXP3 + regulatory T-cell subsets (Benson et al., 2007;
Iwata and Yokota, 2011) and prevented differentiation of pro-
inﬂammatory interleukin (IL)-17-secreting Th17 cells (Bai et al.,
2009; Hundorfean et al., 2012; Nikoopour et al., 2008; Reifen
et al., 2002). Notably, observations of lower levels of pro-inﬂam-
matory cytokines (tumor necrosis factor [TNF]-a, subsequently re-
ferred to as TNF, IL-1b, IL-17), increased levels of regulatory
cytokines (IL-10, TGF-b), and a dose-dependent amelioration of
2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis by ATRA
were sufﬁciently strong for the authors to suggest ATRA as having
therapeutic potential in IBD (Bai et al., 2009). Moreover, ATRA has
been shown to be a critical regulator for barrier protection during
mucosal injuries via up-regulation of tight-junction proteins and
cyclo-oxygenase (Osanai et al., 2007). ATRA has also been shown
to up-regulate the expression of gut-homing receptors, e.g., inte-
grin a4b7 and C–C chemokine receptor type 9 on T-cells in vitro,
which, upon binding to mucosal cascular addresin cell adhesion
molecule 1 and chemokine (C–C motif) ligand 25, respectively,
mediate the migration of Th17 cells and regulatory T cells to the
gut mucosa (Iwata et al., 2004).
Nevertheless, data from studies in primary human cells and
intestinal cell lines as to the effects of retinoids remain limited.
In this in vitro study we evaluated the effects of retinoid derivatives
of vitamin A – ATRA (tretinoin, the major metabolic derivative of
vitamin A), 13-cis-RA (isotretinoin) and 4-oxo-13-cis-retinoic acid
(4-oxo-13-cis-RA, the primary stable metabolite of isotretinoin) –
on lipopolysaccharide (LPS)-induced cytokine release from differ-
entiated monocytic dendritic cells and macrophages, and from cul-
tured human acute monocytic leukaemia (THP)-1 cells, and also
their effects on human intestinal epithelial cell integrity. The effect
of retinoids in in vivo animal models has been investigated also
(data to be published separately).2. Materials and methods
2.1. Retinoids
ATRA, 13-cis-RA and 4-oxo-13-cis-RA (RO22-6595, Roche, Swit-
zerland) were dissolved in dimethylsulfoxide (40 mg/mL), diluted
in phosphate buffered saline (PBS), and tested at ﬁnal concentra-
tions of 0.01–5.0 lg/mL.
2.2. Human donors
Peripheral blood from healthy donors (two males and ﬁve fe-
males, aged 25–43 years) was obtained after oral consent, and in
accordance with the guidelines of the ethical committee of Canton
Zurich.
2.3. Isolation of human peripheral blood monocytes
Peripheral blood mononuclear cells (PBMCs) were isolated from
80 mL of peripheral blood according to the Ficoll gradient centri-
fugation method. PBMCs were incubated with magnetic micro-beads (130-091-153, Monocyte Isolation Kit II, Miltenyi Biotec,
Bergisch Gladbach, Germany) in accordance with the manufac-
turer’s protocol, and ﬁnal isolation of monocytes was achieved
using a magnetic cell sorter (AutoMACS, Miltenyi Biotec,
Germany).
2.4. Generation of in vitro-differentiated dendritic cells (ivDCs)
PBMCs were differentiated into dendritic cells using an estab-
lished protocol (Rogler et al., 1998); monocytes were cultivated
in ﬂasks for 1 week under optimal conditions (37 C, 5% CO2, 95%
relative humidity [RH]) with 5 ng/mL IL-4 and 50 ng/mL granulo-
cyte–macrophage colony-stimulating factor (GM-CSF).
2.5. Generation of in vitro-differentiated macrophages (ivMACs)
As described above for ivDCs, peripheral blood monocytes were
differentiated into macrophages based on the established protocol
cited, with monocytes being cultivated in Teﬂon bags for 1 week
under optimal conditions (37 C, 5% CO2, 95% RH). Differentiated
macrophages were detached from the Teﬂon bags by incubation
at 4 C.
2.6. Cell culture (THP-1 and Caco-2 cells)
The monocytic/macrophage-like THP-1 cell line was cultivated
in Roswell Park Memorial Institute medium containing 10% fetal
calf serum (FCS), supplemented with penicillin (100 U/mL) and
streptomycin (100 lg/mL) under standard conditions (37 C, 5%
CO2, 95% RH). Human epithelial colorectal adenocarcinoma
(Caco-2) cells were grown in high glucose Dulbecco’s Modiﬁed
Eagle’s Medium containing 10% FCS, supplemented with penicillin
(100 U/mL) and streptomycin (100 lg/mL) under recommended
conditions (37 C, 10% CO2, 95% RH). For both cell lines, passaging
was carried out according to the guidelines of the American Type
Culture Collection (ATCC, 2012).
2.7. Stimulation of cytokine response
The inﬂuence of retinoids on the LPS-induced cytokine re-
sponse of ivDCs, ivMACs and THP-1 cells was evaluated in each
cell type using the same experimental methodology. Primary
cells were adjusted to a density of 1  106 cells/mL and plated
onto 96-well plates (100 lL/well). THP-1 cells were incubated
in six-well plates at a density of 7  105 cells/mL. Retinoids were
added to the medium (0.01, 0.1, 1.0 and 5.0 lg/mL) for ivDCs,
ivMACs and THP-1 cells, and pre-incubated for 1 h prior to
stimulation with LPS (to a ﬁnal concentration of 100 ng/ml) for
a further 48 h at 37 C.
Incubation medium was collected and processed for cytokine
analysis (Rules-Based Medicine, Austin, Texas, USA) using Human
Cytokine MAP A 1.0 array. Levels of IL-15 were below the detec-
tion limit of the assay and were excluded from the analysis.
For studies in ivDCs, cytokine response data shown are based
on at least six (LPS-induced) and at least four (no LPS) indepen-
dently performed experiments, each corresponding to a different
donor. In ivMACs, these data (both LPS-induced and no LPS)
were each based on at least four independently performed
experiments, each corresponding to a different donor. Data
shown for cytokine response in THP-1 cells are based on three
independent experiments.
2.8. Intestinal epithelial cell permeability
To investigate a potential role of retinoid derivatives of vitamin
A on intestinal permeability, the diffusion of ﬂuorescently-labeled
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with retinoid. Caco-2 cells were grown onto trans-well inserts of
0.4 lm pore size for 3 weeks to reach maximum conﬂuency. Cells
were subsequently pre-incubated with different concentrations
of retinoids (0.01, 0.1, 1.0 and 5.0 lg/mL) for 48 h. Caco-2 monolay-
ers were washed once with PBS and ﬂuorescein isothiocyanate
(FITC)-labeled 10 kDA dextran (Sigma–Aldrich, St. Louis, USA)
and added to the apical chambers at a ﬁnal concentration of
0.2 mg/mL. Ethylenediaminetetraacetic acid (EDTA) 0.1 mM was
used in parallel as a positive control. Following overnight incuba-
tion, media from the basal chambers were collected and analyzed
for FITC-dextran leakage using spectroﬂuorometric analysis (Bio-
tek, Winooski, USA). Data are provided based on mean values from
two independent representative experiments.
2.9. Statistical analysis
Based on a paired analysis of LPS-induced responses, statistical
signiﬁcance was determined using a one-way analysis of variance
with Tukey’s multi-comparison post-test using Graph Pad Prism 5
software (GraphPad Software, La Jolla, California, USA).3. Results
3.1. Cytokine response
3.1.1. ivDCs
In the presence of LPS, ATRA signiﬁcantly inhibited the LPS-
induced release of pro-inﬂammatory cytokines such as TNF, IL-6,
macrophage inﬂammatory protein (MIP)-1a and MIP-1b fromFig. 1. The inﬂuence of retinoids on LPS-induced release of inﬂammatory targets from ivD
after incubation with retinoids (1 lg/mL) and stimulation with LPS (100 ng/mL). Bars rep
to different donors. ⁄P < 0.05; ⁄⁄⁄P < 0.001.ivDCs (Fig. 1); data were consistent across all retinoid concentra-
tions tested (0.01, 0.1, 1.0 and 5.0 lg/mL) and, for clarity, only
1 lg/mL data are shown. Additionally, ATRA and its derivatives sig-
niﬁcantly stimulated the production of monocyte chemotactic pro-
tein (MCP)-1 and vascular endothelial growth factor (VEGF), and
also the anti-inﬂammatory cytokine IL-10 (Fig. 1). Although incu-
bation of ivDCs with retinoids affected the LPS-induced release of
several other cytokine targets implicated in the inﬂammatory re-
sponse, none of these changes were signiﬁcant (Supplementary
Fig. I).
In the absence of LPS, incubation with ATRA and 13-cis-RA each
induced increases in GM-CSF, MCP-1 and VEGF from ivDCs, which
were signiﬁcant at the highest doses tested; a similar but non-
signiﬁcant trend being evident for 4-oxo-13-cis-RA (Fig. 2). There
was little or no change in the cytokine response for IL-1a, IL-1
receptor antagonist (IL-1RA), IL-4, and IL-18. Although there was
a tendency for the retinoids tested to induce the release of intercel-
lular adhesion molecule-1 (ICAM-1), interferon (IFN)-c, IL-1b, lym-
photoxin-a, matrix metalloproteinase (MMP)-2 and stem cell
factor, and to also inhibit the release of IL-10, IL-6, MIP-1a, MIP-
1b and TNF, these changes were modest and in all cases not statis-
tically signiﬁcant (Supplementary Fig. II).3.1.2. ivMACs
In the presence of LPS, similarly signiﬁcant increases were seen
in the release of MCP-1, eotaxin-1, and VEGF following incubation
of ivMACs with each retinoid (Fig. 3, consistent responses were
again evident across all retinoid concentrations and, for clarity,
only 1 lg/mL data are shown). Additionally, signiﬁcant reductions
were seen in the LPS-induced release of the pro-inﬂammatoryCs. Cell-treated supernatants were analyzed for different cytokines and chemokines
resent mean + SEM values from at least six independent experiments corresponding
Fig. 2. The inﬂuence of retinoids on the release of inﬂammatory targets from ivDCs. Cell-treated supernatants were analyzed for different cytokines and chemokines after
incubation with different concentrations of retinoids (0.01, 0.1, 1.0 and 5.0 lg/mL). Bars represent mean + SEM values from at least four independent experiments
corresponding to different donors. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
Fig. 3. The inﬂuence of retinoids on LPS-induced release of inﬂammatory targets from ivMACs. Cell-treated supernatants were analyzed for different cytokines and
chemokines after incubation with retinoids (1 lg/mL) and stimulation with LPS (100 ng/mL). Bars represent mean + SEM values from at least four independent experiments
corresponding to different donors. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
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sistent with those seen for ivDCs. Incubation of ivMACs with reti-
noids also tended to promote increased LPS-induced release of
IL-8, IL-10, IL-1b and IL-1RA and reduction in the release of
IL-1a, but these changes were not statistically signiﬁcant (Supple-
mentary Fig. III). Moreover, no changes were evident in the
responses for ICAM-1, IL-18, and MMP-3.
In the absence of LPS, comparable responses to those observed
for ivDCs were seen in that the retinoids tested induced the release
of MCP-1, eotaxin-1, IL-8 and VEGF; for eotaxin-1 and VEGF, re-
sponses appeared dose dependent (albeit non-signiﬁcant) for all
retinoids tested (Fig. 4). There was little or no change in the cyto-
kine response for ICAM-1, IL-1a, IL-1b, and IL-6. Although there
was a tendency for the retinoids tested to induce the release ofIL-10, IL-18 and MIP-1a as well as inhibit the release of pro-inﬂam-
matory IFN-c, IL-1RA, MIP-1b, MMP-3 and TNF, these changes
were modest and in all cases not statistically signiﬁcant (Supple-
mentary Fig. IV).
3.1.3. THP-1 cells
The effects of retinoids on LPS-induced cytokine response from
THP-1 cells were generally similar to those observed for both ivDCs
and ivMACs. Pre-incubation of THP-1 cells with retinoids resulted
in reduced LPS-induced release of IL-6 as well as increased release
of IL-8 (particularly evident for the latter at the highest retinoid
concentrations tested) and MCP-1 (Fig. 5); these responses were
evident for each of the retinoids tested (Fig. 5) and generally con-
sistent with responses seen in ivDCs and ivMACs (Figs. 1–4).
Fig. 4. The inﬂuence of retinoids on the release of inﬂammatory targets from ivMACs. Cell-treated supernatants were analyzed for different cytokines and chemokines after
incubation with different concentrations of retinoids (0.01, 0.1, 1.0 and 5.0 lg/mL). Bars represent mean + SEM values from at least four independent experiments
corresponding to different donors. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
Fig. 5. The inﬂuence of retinoids on the release of inﬂammatory targets from THP-1 cells. Cell-treated supernatants were analyzed for different cytokines and chemokines
after incubation with different concentrations of retinoids (0.01, 0.1, 1.0 and 5.0 lg/mL) either in the absence (light bars) or presence (dark bars) of LPS (1 lg/mL). Bars
indicate mean values from three independent experiments.
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Incubation of human Caco-2 cells with different concentrations
each of ATRA, isotretinoin and 4-oxo-cis-RA resulted in no signiﬁ-
cant change in permeability of Caco-2 monolayers at all doses
tested (Supplementary Fig. V). FITC-labeled dextran was observed
to be translocated effectively in EDTA-treated monolayers, a ﬁnd-
ing consistent with the known potent adverse effect of this com-
pound on tight-junction integrity (Tomita et al., 1994).4. Discussion
Retinoid treatment has recently been suggested to play a path-
ophysiological role in the development of chronic IBD, a contention
based essentially on several case reports (Crockett et al., 2009;
Shale et al., 2009). However, key basic research data appear to con-
tradict this in showing retinoids to be mainly associated with anti-
inﬂammatory activity (Bai et al., 2009; Straus and Glass, 2007) and,
for example, substitution of vitamin A in a TNBS rat model of colitis
was found to ameliorate colitis according to histological scores and
weight curves (Bai et al., 2009; Reifen et al., 2002). While the
molecular effects of vitamin A and its retinoid derivatives are well
understood based on studies in multiple in vitro settings (Amann
et al., 2011; Delacroix et al., 2010; Li et al., 2006; Norris et al.,
1987; Wada et al., 2009), the data available from intestinal cell
lines and primary human cells are generally limited; a situation
that has led to speculation recently as to whether retinoids are
harmful or beneﬁcial to the GI tract (Crockett et al., 2010; Reddy
et al., 2006), and suggested need for further study.
The ﬁndings from this in vitro study, designed to evaluate the
effect of retinoids on cytokine release and suppression, and GI
integrity in various human immune cell types, clearly demon-
strate that pre-treatment of ivDCs, ivMACs and cultured human
THP-1 cells with ATRA, or the derivatives tested, promotes an
anti-inﬂammatory pattern of cytokine release with little or no
change in epithelial cell line integrity. This speciﬁcally relates
to signiﬁcant inhibition of LPS-induced release of pro-inﬂamma-
tory cytokines such as TNF and IL-6, and also of MIP-1a and
MIP-1b. These observations, and also the fact that all retinoids
tested stimulated the release of the anti-inﬂammatory cytokine
IL-10 from ivDCs and ivMACs, collectively conﬁrm that retinoids
promote a pattern of cytokine release that is more anti-inﬂam-
matory than pro-inﬂammatory. Such a pattern is, in fact, consis-
tent with recent in vitro and in vivo studies. For example,
retinoids such as ATRA play a crucial role in the differentiation
of T-cells by inducing the differentiation of gut-homing
FOXP3 + regulatory T-cells and preventing the differentiation of
pro-inﬂammatory IL-17-secreting Th17 cells (including in human
colonic biopsies) (Bai et al., 2009; Iwata and Yokota, 2011); they
also promote the homing of Th17 cells and regulatory T cells to
the GI mucosa and stimulation of antigen-presenting cells to se-
crete IL-10 (Benson et al., 2007; Crockett et al., 2009; Hundorf-
ean et al., 2012; Nikoopour et al., 2008). Additionally, ATRA
treatment has been shown to reduce inﬂammation, mucosal
damage and myeloperoxidase activity in the mouse TNBS colitis
model. In this study, lamina propria mononuclear cells from
ATRA-treated animals were reported to produce lower levels of
pro-inﬂammatory TNF, IL-1b, and IL-17 and release more regula-
tory cytokines (IL-10 and TGF-b) (Bai et al., 2009).
In the absence of LPS, incubation with each of the retinoids
tested was similarly associated with little, or no, effect on the re-
lease of inﬂammatory mediators from all cell types; an effect that
was observed over a broad range of retinoid concentrations (0.01,
0.1, 1.0 and 5 lg/mL). Under these conditions, the retinoids tested
induced the release of eotaxin-1, MCP-1 and IL-8, i.e. chemokinetargets involved in the migration of immune cells, and also GM-CSF
and VEGF, from ivDCs and ivMACs. Perhaps most notable is the
markedly increased release of GM-CSF, MCP-1 and VEGF in re-
sponse to retinoids alone. There is now strong evidence, including
studies both in GM-CSF knockout mice (Xu et al., 2008) and in
human subjects (Goldstein et al., 2011), to support a key role of
GM-CSF in activating and maintaining intestinal innate immune
barrier function. Collectively, such ﬁndings have fostered the
emergence of CSFs as a potential tool for the treatment of IBD
(Barahona-Garrido and Yamamoto-Furusho, 2008) and, in fact,
recent controlled clinical trials have shown treatment with recom-
binant human GM-CSF to decrease disease severity and improve
the quality of life of patients with active CD (Goldstein et al.,
2011; Korzenik et al., 2005). It follows, therefore, that the reti-
noid-induced release of GM-CSF reported here, as distinct from
LPS-induced responses, would provide potential beneﬁt to the GI
environment, particularly in pathological states such as IBD.
A similar view could be taken regarding the observed changes
in MCP-1. This key target, together with IL-10, is crucial for the reg-
ulation of immune responses against commensal bacteria by intes-
tinal macrophages (Takada et al., 2010) and has been shown also to
exert a beneﬁcial effect on dextran sodium sulfate (DSS)-induced
colitis in mice (Maharshak et al., 2010). Thus, as for GM-CSF, the
retinoid-induced release of MCP-1 seen in this study, both in the
presence and absence of LPS, may similarly preclude a beneﬁcial
effect of this chemokine in steady-state gut homeostasis. In con-
trast, however, overexpression of VEGF-A has been shown to be
associated with deterioration in disease status in mice with DSS-
induced colitis, levels correlating with increased angiogenesis
and leukocyte adhesion in the intestine (Scaldaferri et al., 2009),
while increased levels of VEGF are usually observed in human sub-
jects with IBD (Tsiolakidou et al., 2008). The release of VEGF might,
therefore, be expected to convey potentially negative effects on
intestinal immunology. To counterbalance this argument, VEGF
has also been observed to inhibit the apoptosis of intestinal epithe-
lial cells – thus preventing bacterial translocation across ileal mu-
cosa (Nakajima et al., 2007) – while levels of VEGF expression are
reported as not being associated with disease activity in patients
with IBD (Alkim et al., 2012). Nevertheless, until more data become
available relating to the effect of VEGF on maintenance of gut
homeostasis, it is perhaps prudent that caution is exercised in
assessing the overall effect of this cytokine target on the intestinal
milieu.
All retinoids tested were also found to have little or no adverse
effect on the permeability of Caco-2 monolayers. This was also evi-
dent at all doses tested and is in apparent conﬂict with a relatively
early in vitro study, which showed that the permeability of the
Caco-2 monolayer, as measured by transepithelial electric resis-
tance and [3H]-mannitol ﬂux, was enhanced by ATRA. Given the
known association between vitamin A deﬁciency and impairment
in intestinal integrity, the authors considered this surprising and
attributed increased permeability to an unknown mechanism(s)
and not altered tight-junction protein expression (Baltes et al.,
2004). The ﬁndings with regard to permeability are, however, con-
sistent with reported protective effects of retinoids for the GI mu-
cosa. For example, gastric mucosal protection (against
indomethacin treatment) was seen in healthy persons and in pa-
tients with gastric ulcer and duodenal ulcer without any inhibition
of gastric acid secretion (Mózsik et al., 2001), while increased mu-
cin production in the presence of retinoids was considered to con-
tradict any putative drying effect of retinoid analogues on the
intestinal epithelium as a causal contributor of IBD (Gray et al.,
2001; Tan and Cheng, 2007).
In summary, these in vitro ﬁndings conﬁrm that retinoid deriv-
atives of vitamin A provoke an LPS-induced cytokine response from
human immune cells consistent with an anti-inﬂammatory pattern
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ability. As such, these studies do not support retinoids as present-
ing a metabolic milieu dangerous to the GI tract. These ﬁndings are
consistent with studies in in vivo animal models of colitis (to be
published separately).Conﬂict of interest
This study was supported by F. Hoffmann-La Roche Ltd., Basel,
Switzerland and also by research grants from the Swiss National
Science Foundation to SRV (Grant Nos. 320000-114009/3 and
32473B_135694/1), to GR (Grant No. 310030-120312), and by
the Swiss IBD Cohort (Grant No. 3347CO-108792) and by the
Zurich Center for Integrative Human Physiology (ZIHP) of the
University of Zurich.
The funding source had no inﬂuence on the study design, collec-
tion, analysis and interpretation of data, the writing of the report
and in the decision to submit the paper for publication. Study de-
sign, collection, analysis and interpretation of data was exclusively
performed by the authors.
Acknowledgements
The authors would like to thank Kirstin Atrott for technical sup-
port, and also Dr. Harald Kropshofer and Dr. Lutz Müller from
Roche for helpful discussions and assistance during the course of
these studies.
Medical writing support for this paper was provided by Carl V.
Felton PhD of Prime Healthcare, supported by Roche. Responsibil-
ity for opinions, conclusions and interpretation of data lies with the
authors.Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.tiv.2013.03.013.
References
Alkim, C., Sakiz, D., Alkim, H., Livaoglu, A., Kendir, T., Demirsoy, H., Erdem, L.,
Akbayir, N., Sokmen, M., 2012. Thrombospondin-1 and VEGF in inﬂammatory
bowel disease. Libyan J. Med. 7, 8942.
Amann, P.M., Eichmüller, S.B., Schmidt, J., Bazhin, A.V., 2011. Regulation of gene
expression by retinoids. Curr. Med. Chem. 18, 1405–1412.
ATCC, 2012. http://www.atcc.org/LinkClick.aspx?ﬁleticket=iiksZHcIIfQ%3D
&tabid=1570&mid=5414> [accessed 09.08.12].
Avidan, B., Sakhnini, E., Lahat, A., Lang, A., Koler, M., Zmora, O., Bar-Meir, S.,
Chowers, Y., 2005. Risk factors regarding the need for a second operation in
patients with Crohn’s disease. Digestion 72, 248–253.
Bai, A., Lu, N., Guo, Y., Liu, Z., Chen, J., Peng, Z., 2009. All-trans retinoic acid down-
regulates inﬂammatory responses by shifting the Treg/Th17 proﬁle in human
ulcerative and murine colitis. J. Leukoc. Biol. 86, 959–969.
Baltes, S., Nau, H., Lampen, A., 2004. All-trans retinoic acid enhances differentiation
and inﬂuences permeability of intestinal Caco-2 cells under serum-free
conditions. Dev. Growth Differ. 46, 503–514.
Barahona-Garrido, J., Yamamoto-Furusho, J.K., 2008. New treatment options in the
management of IBD - focus on colony stimulating factors. Biologics 2, 501–504.
Barrett, J.C., Hansoul, S., Nicolae, D.L., Cho, J.H., Duerr, R.H., Rioux, J.D., Brant, S.R.,
Silverberg, M.S., Taylor, K.D., Barmada, M.M., Bitton, A., Dassopoulos, T., Datta,
L.W., Green, T., Grifﬁths, A.M., Kistner, E.O., Murtha, M.T., Regueiro, M.D., Rotter,
J.I., Schumm, L.P., Steinhart, A.H., Targan, S.R., Xavier, R.J., NIDDK IBD Genetics
Consortium, Libioulle, C., Sandor, C., Lathrop, M., Belaiche, J., Dewit, O., Gut, I.,
Heath, S., Laukens, D., Mni, M., Rutgeerts, P., Van Gossum, A., Zelenika, D.,
Franchimont, D., Hugot, J.P., de Vos, M., Vermeire, S., Louis, E., Belgian-French
IBD Consortium, Wellcome Trust Case Control Consortium, Cardon, L.R.,
Anderson, C.A., Drummond, H., Nimmo, E., Ahmad, T., Prescott, N.J., Onnie,
C.M., Fisher, S.A., Marchini, J., Ghori, J., Bumpstead, S., Gwilliam, R., Tremelling,
M., Deloukas, P., Mansﬁeld, J., Jewell, D., Satsangi, J., Mathew, C.G., Parkes, M.,
Georges, M., Daly, M.J. 2008. Genome-wide association deﬁnes more than 30
distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40, 955–962
Benson, M.J., Pino-Lagos, K., Rosemblatt, M., Noelle, R.J., 2007. All-trans retinoic acid
mediates enhanced T reg cell growth, differentiation, and gut homing in the face
of high levels of co-stimulation. J. Exp. Med. 204, 1765–1774.Cámara, R.J., Begré, S., von Känel, R., 2010. The effect of stress-relieving
interventions on inﬂammatory bowel disease: quality assessment of 10
therapeutic studies. Z. Psychosom. Med. Psychother. 56, 116–135.
Cosnes, J., 2010. Smoking, physical activity, nutrition and lifestyle: environmental
factors and their impact on IBD. Dig. Dis. 28, 411–417.
Cosnes, J., Carbonnel, F., Beaugerie, L., Le Quintrec, Y., Gendre, J.P., 1996. Effects of
cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology
110, 424–431.
Cosnes, J., Beaugerie, L., Carbonnel, F., Gendre, J.P., 2001. Smoking cessation and the
course of Crohn’s disease: an intervention study. Gastroenterology 120, 1093–
1099.
Crockett, S.D., Gulati, A., Sandler, R.S., 2009. A causal association between
isotretinoin and inﬂammatory bowel disease has yet to be established. Am. J.
Gastroenterol. 104, 2387–2393.
Crockett, S.D., Porter, C.Q., Martin, C.F., Sandler, R.S., Kappelman, M.D., 2010.
Isotretinoin use and the risk of inﬂammatory bowel disease: a case-control
study. Am. J. Gastroenterol. 105, 1986–1993.
Danese, S., Sans, M., Fiocchi, C., 2004. Inﬂammatory bowel disease: the role of
environmental factors. Autoimmun. Rev. 3, 394–400.
Delacroix, L., Moutier, E., Altobelli, G., Legras, S., Poch, O., Choukrallah, M.A., Bertin,
I., Jost, B., Davidson, I., 2010. Cell-speciﬁc interaction of retinoic acid receptors
with target genes in mouse embryonic ﬁbroblasts and embryonic stem cells.
Mol. Cell. Biol. 30, 231–244.
Goldstein, J.I., Kominsky, D.J., Jacobson, N., Bowers, B., Regalia, K., Austin, G.L.,
Youseﬁ, M., Falta, M.T., Fontenot, A.P., Gerich, M.E., Golden-Mason, L., Colgan,
S.P., 2011. Defective leukocyte GM-CSF receptor (CD116) expression and
function in inﬂammatory bowel disease. Gastroenterology 141, 208–216.
Gray, T., Koo, J.S., Nettesheim, P., 2001. Regulation of mucous differentiation and
mucin gene expression in the tracheobronchial epithelium. Toxicology 160, 35–
46.
Hou, J., El-Serag, H., Sellin, J., Thirumurthi, S., 2011a. Inﬂammatory bowel disease
characteristics and treatment in Hispanics and Caucasians. Dig. Dis. Sci. 56,
1476–1481.
Hou, J.K., Abraham, B., El-Serag, H., 2011b. Dietary intake and risk of developing
inﬂammatory bowel disease: a systematic review of the literature. Am. J.
Gastroenterol. 106, 563–573.
Hundorfean, G., Neurath, M.F., Mudter, J., 2012. Functional relevance of T helper 17
(Th17) cells and the IL-17 cytokine family in inﬂammatory bowel disease.
Inﬂamm. Bowel Dis. 18, 180–186.
Iwata, M., Yokota, A., 2011. Retinoic acid production by intestinal dendritic cells.
Vitam. Horm. 86, 127–152.
Iwata, M., Hirakiyama, A., Eshima, Y., Kagechika, H., Kato, C., Song, S.Y., 2004.
Retinoic acid imprints gut-homing speciﬁcity on T cells. Immunity 21, 527–538.
Järnerot, G., Järnmark, I., Nilsson, K., 1983. Consumption of reﬁned sugar by patients
with Crohn’s disease, ulcerative colitis, or irritable bowel syndrome. Scand. J.
Gastroenterol. 18, 999–1002.
Kane, S.V., Flicker, M., Katz-Nelson, F., 2005. Tobacco use is associated with
accelerated clinical recurrence of Crohn’s disease after surgically induced
remission. J. Clin. Gastroenterol. 39, 32–35.
Katschinski, B., Logan, R.F., Edmond, M., Langman, M.J., 1988. Smoking
and sugar intake are separate but interactive risk factors in Crohn’s disease.
Gut 29, 1202–1206.
Korzenik, J.R., Dieckgraefe, B.K., Valentine, J.F., Hausman, D.F., Gilbert, M.J., 2005.
Sargramostim in Crohn’s Disease Study Group. Sargramostim for active Crohn’s
disease. N. Engl. J. Med. 352, 2193–2201.
Latella, G., Fiocchi, C., Caprili, R., 2010. News from the ‘‘5th International
Meeting on Inﬂammatory Bowel Diseases’’ CAPRI 2010. J. Crohns Colitis. 4,
690–702.
Levenstein, S., 2002. Psychosocial factors in peptic ulcer and inﬂammatory bowel
disease. J. Consult. Clin. Psychol. 70, 739–750.
Li, G., Yin, W., Chamberlain, R., Hewett-Emmett, D., Roberts, J.N., Yang, X., Lippman,
S.M., Clifford, J.L., 2006. Identiﬁcation and characterization of the human
retinoid X receptor alpha gene promoter. Genetics 372, 118–127.
Maharshak, N., Hart, G., Ron, E., Zelman, E., Sagiv, A., Arber, N., Brazowski, E.,
Margalit, R., Elinav, E., Shachar, I., 2010. CCL2 (pM levels) as a therapeutic agent
in inﬂammatory bowel disease models in mice. Inﬂamm. Bowel Dis. 16, 1496–
1504.
Martini, G.A., Brandes, J.W., 1976. Increased consumption of reﬁned carbohydrates
in patients with Crohn’s disease. Klin. Wochenschr. 54, 367–371.
Mathew, C.G., 2008. New links to the pathogenesis of Crohn’s disease provided by
genome-wide association scans. Nat. Rev. Genet. 9, 9–14.
Mózsik, G., Bódis, B., Figler, M., Király, A., Karádi, O., Pár, A., Rumi, G., Sütõ, G., Tóth,
G., Vincze, A., 2001. Mechanisms of action of retinoids in gastrointestinal
mucosal protection in animals, human healthy subjects and patients. Life Sci.
69, 3103–3112.
Nakajima, T., Ueda, T., Takeyama, Y., Yasuda, T., Shinzeki, M., Sawa, H., Kuroda, Y.,
2007. Protective effects of vascular endothelial growth factor on intestinal
epithelial apoptosis and bacterial translocation in experimental severe acute
pancreatitis. Pancreas 34, 410–416.
Nguyen, G.C., Torres, E.A., Regueiro, M., Bromﬁeld, G., Bitton, A., Stempak, J.,
Dassopoulos, T., Schumm, P., Gregory, F.J., Grifﬁths, A.M., Hanauer, S.B., Hanson,
J., Harris, M.L., Kane, S.V., Orkwis, H.K., Lahaie, R., Oliva-Hemker, M., Pare, P.,
Wild, G.E., Rioux, J.D., Yang, H., Duerr, R.H., Cho, J.H., Steinhart, A.H., Brant, S.R.,
Silverberg, M.S., 2006. Inﬂammatory bowel disease characteristics among
African Americans, Hispanics, and non-Hispanic Whites: characterization of a
large North American cohort. Am. J. Gastroenterol. 101, 1012–1023.
1532 K.A. Wojtal et al. / Toxicology in Vitro 27 (2013) 1525–1532Nikoopour, E., Schwartz, J.A., Singh, B., 2008. Therapeutic beneﬁts of
regulating inﬂammation in autoimmunity. Inﬂamm. Allergy Drug Targets 7,
203–210.
Norris, D.A., Osborn, R., Robinson, W., Tonnesen, M.G., 1987. Isotretinoin produces
signiﬁcant inhibition of monocyte and neutrophil chemotaxis in vivo in patients
with cystic acne. J. Invest. Dermatol. 89, 38–43.
Osanai, M., Nishikiori, N., Murata, M., Chiba, H., Kojima, T., Sawada, N., 2007. Cellular
retinoic acid bioavailability determines epithelial integrity: role of retinoic acid
receptor alpha agonists in colitis. Mol. Pharmacol. 71, 250–258.
Reddy, D., Siegel, C.A., Sands, B.E., Kane, S., 2006. Possible association between
isotretinoin and inﬂammatory bowel disease. Am. J. Gastroenterol. 101, 1569–
1573.
Reifen, R., Nur, T., Ghebermeskel, K., Zaiger, G., Urizky, R., Pines, M., 2002. Vitamin A
deﬁciency exacerbates inﬂammation in a rat model of colitis through activation
of nuclear factor-kappaB and collagen formation. J. Nutr. 132, 2743–2747.
Rogler, G., 2011. Interaction between susceptibility and environment: examples
from the digestive tract. Dig. Dis. 29, 136–143.
Rogler, G., Hausmann, M., Vogl, D., Aschenbrenner, E., Andus, T., Falk, W., Andreesen,
R., Schölmerich, J., Gross, V., 1998. Isolation and phenotypic characterization of
colonic macrophages. Clin. Exp. Immunol. 112, 205–215.
Scaldaferri, F., Vetrano, S., Sans, M., Arena, V., Straface, G., Stigliano, E., Repici, A.,
Sturm, A., Malesci, A., Panes, J., Yla-Herttuala, S., Fiocchi, C., Danese, S., 2009.
VEGF-A links angiogenesis and inﬂammation in inﬂammatory bowel disease
pathogenesis. Gastroenterology 136 (585–95), e5.
Shale, M., Kaplan, G.G., Panaccione, R., Ghosh, S., 2009. Isotretinoin and
intestinal inﬂammation: what gastroenterologists need to know. Gut 58,
737–741.Silkoff, K., Hallak, A., Yegena, L., Rozen, P., Mayberry, J.F., Rhodes, J., Newcombe, R.G.,
1980. Consumption of reﬁned carbohydrate by patients with Crohn’s disease in
Tel-Aviv-Yafo. Postgrad. Med. J. 56, 842–846.
Straus, D.S., Glass, C.K., 2007. Anti-inﬂammatory actions of PPAR ligands: new
insights on cellular and molecular mechanisms. Trends Immunol. 28, 551–558.
Takada, Y., Hisamatsu, T., Kamada, N., Kitazume, M.T., Honda, H., Oshima, Y., Saito,
R., Takayama, T., Kobayashi, T., Chinen, H., Mikami, Y., Kanai, T., Okamoto, S.,
Hibi, T., 2010. Monocyte chemoattractant protein-1 contributes to gut
homeostasis and intestinal inﬂammation by composition of IL-10-producing
regulatory macrophage subset. J. Immunol. 184, 2671–2676.
Tan, S., Cheng, P.W., 2007. Mucin biosynthesis: identiﬁcation of the cis-regulatory
elements of human C2GnT-M gene. Am. J. Respir. Cell Mol. Biol. 36, 737–745.
Thornton, J.R., Emmett, P.M., Heaton, K.W., 1979. Diet and Crohn’s disease:
characteristics of the pre-illness diet. Br. Med. J. 2, 762–764.
Tomita, M., Hayashi, M., Awazu, S., 1994. Comparison of absorption-enhancing
effect between sodium caprate and disodium ethylenediaminetetraacetate in
Caco-2 cells. Biol. Pharm. Bull. 17, 735–753.
Torkamani, A., Topol, E.J., Schork, N.J., 2008. Pathway analysis of seven common
diseases assessed by genome-wide association. Genomics 92, 265–272.
Tsiolakidou, G., Koutroubakis, I.E., Tzardi, M., Kouroumalis, E.A., 2008. Increased
expression of VEGF and CD146 in patients with inﬂammatory bowel disease.
Dig. Liver Dis. 40, 673–679.
Wada, Y., Hisamatsu, T., Kamada, N., Okamoto, S., Hibi, T., 2009. Retinoic acid
contributes to the induction of IL-12-hypoproducing dendritic cells. Inﬂamm.
Bowel Dis. 15, 1548–1556.
Xu, Y., Hunt, N.H., Bao, S., 2008. The role of granulocyte macrophage-colony-
stimulating factor in acute intestinal inﬂammation. Cell Res. 18, 1220–1229.
